Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction ; volume:408 ; number:1 ; day:6 ; month:9 ; year:2023 ; pages:1-11 ; date:12.2023
Langenbeck's archives of surgery ; 408, Heft 1 (6.9.2023), 1-11, 12.2023
- Urheber
-
Feka, Joy
Jomrich, Gerd
Winkler, Daniel
Ilhan-Mutlu, Ayseguel
Kristo, Ivan
Paireder, Matthias
Rieder, Erwin
Bologheanu, Milena
Asari, Reza
Schoppmann, Sebastian Friedrich
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00423-023-03093-y
- URN
-
urn:nbn:de:101:1-2023111714202211411694
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Feka, Joy
- Jomrich, Gerd
- Winkler, Daniel
- Ilhan-Mutlu, Ayseguel
- Kristo, Ivan
- Paireder, Matthias
- Rieder, Erwin
- Bologheanu, Milena
- Asari, Reza
- Schoppmann, Sebastian Friedrich
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
A proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma
Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
A proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma
Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
A proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma
Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis